Acute promyelocytic leukemia cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
Category |
Shyam Patel (talk | contribs) No edit summary |
||
| Line 2: | Line 2: | ||
{{Acute promyelocytic leukemia}} | {{Acute promyelocytic leukemia}} | ||
{{cmg}} {{shyam}} | |||
==Cost-effectiveness of therapy== | |||
A limited number of cost-effectiveness studies have been performed in acute promyelocytic leukemia. One comprehensive cost-effective analysis studied the costs of therapy. | |||
*The combination of all-''trans'' retinoic acid plus idarubicin was more cost-effective than the combination of all-''trans'' retinoic acid plus cytarabine plus additional chemotherapy.<ref name="pmid26361645">{{cite journal| author=Tallman M, Lo-Coco F, Barnes G, Kruse M, Wildner R, Martin M et al.| title=Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States. | journal=Clin Lymphoma Myeloma Leuk | year= 2015 | volume= 15 | issue= 12 | pages= 771-7 | pmid=26361645 | doi=10.1016/j.clml.2015.07.634 | pmc=5028894 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26361645 }} </ref> | |||
**The incremental cost-effective ratio for all-''trans'' retinoic acid plus idarubicin was $2933 per life year saved and $3122 per quality-adjusted life year gained.<ref name="pmid26361645">{{cite journal| author=Tallman M, Lo-Coco F, Barnes G, Kruse M, Wildner R, Martin M et al.| title=Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States. | journal=Clin Lymphoma Myeloma Leuk | year= 2015 | volume= 15 | issue= 12 | pages= 771-7 | pmid=26361645 | doi=10.1016/j.clml.2015.07.634 | pmc=5028894 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26361645 }} </ref> | |||
*The combination of all-''trans'' retinoic acid plus arsenic trioxide was more cost-effective than all-''trans'' retinoic acid plus idarubicin.<ref name="pmid26361645">{{cite journal| author=Tallman M, Lo-Coco F, Barnes G, Kruse M, Wildner R, Martin M et al.| title=Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States. | journal=Clin Lymphoma Myeloma Leuk | year= 2015 | volume= 15 | issue= 12 | pages= 771-7 | pmid=26361645 | doi=10.1016/j.clml.2015.07.634 | pmc=5028894 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26361645 }} </ref> | |||
**The incremental cost-effective ratio for all-''trans'' retinoic acid plus arsenic trioxide was $4512 per life year saved and $5614 per quality-adjusted life year gained.<ref name="pmid26361645">{{cite journal| author=Tallman M, Lo-Coco F, Barnes G, Kruse M, Wildner R, Martin M et al.| title=Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States. | journal=Clin Lymphoma Myeloma Leuk | year= 2015 | volume= 15 | issue= 12 | pages= 771-7 | pmid=26361645 | doi=10.1016/j.clml.2015.07.634 | pmc=5028894 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26361645 }} </ref> | |||
==References== | ==References== | ||
Revision as of 03:50, 21 May 2018
|
Acute promyelocytic leukemia Microchapters |
|
Differentiating Acute promyelocytic leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Acute promyelocytic leukemia cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Acute promyelocytic leukemia cost-effectiveness of therapy |
|
FDA on Acute promyelocytic leukemia cost-effectiveness of therapy |
|
CDC on Acute promyelocytic leukemia cost-effectiveness of therapy |
|
Acute promyelocytic leukemia cost-effectiveness of therapy in the news |
|
Blogs on Acute promyelocytic leukemia cost-effectiveness of therapy |
|
Directions to Hospitals Treating Acute promyelocytic leukemia |
|
Risk calculators and risk factors for Acute promyelocytic leukemia cost-effectiveness of therapy |
Cost-effectiveness of therapy
A limited number of cost-effectiveness studies have been performed in acute promyelocytic leukemia. One comprehensive cost-effective analysis studied the costs of therapy.
- The combination of all-trans retinoic acid plus idarubicin was more cost-effective than the combination of all-trans retinoic acid plus cytarabine plus additional chemotherapy.[1]
- The incremental cost-effective ratio for all-trans retinoic acid plus idarubicin was $2933 per life year saved and $3122 per quality-adjusted life year gained.[1]
- The combination of all-trans retinoic acid plus arsenic trioxide was more cost-effective than all-trans retinoic acid plus idarubicin.[1]
- The incremental cost-effective ratio for all-trans retinoic acid plus arsenic trioxide was $4512 per life year saved and $5614 per quality-adjusted life year gained.[1]
References
- ↑ 1.0 1.1 1.2 1.3 Tallman M, Lo-Coco F, Barnes G, Kruse M, Wildner R, Martin M; et al. (2015). "Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States". Clin Lymphoma Myeloma Leuk. 15 (12): 771–7. doi:10.1016/j.clml.2015.07.634. PMC 5028894. PMID 26361645.